Back to Search
Start Over
A real-world study of inhaled corticosteroid use in patients with severe eosinophilic asthma treated with mepolizumab
- Source :
- Annals of Allergy, Asthma & Immunology; February 2022, Vol. 128 Issue: 2 p184-192.e1
- Publication Year :
- 2022
-
Abstract
- Mepolizumab is a humanized anti-interleukin-5, monoclonal antibody approved for the treatment of patients with severe eosinophilic asthma (SEA). There is limited evidence that mepolizumab can reduce inhaled corticosteroid (ICS) use in these patients.
Details
- Language :
- English
- ISSN :
- 10811206
- Volume :
- 128
- Issue :
- 2
- Database :
- Supplemental Index
- Journal :
- Annals of Allergy, Asthma & Immunology
- Publication Type :
- Periodical
- Accession number :
- ejs58236642
- Full Text :
- https://doi.org/10.1016/j.anai.2021.11.005